Discover the Impact of Epidiolex: Jazz Pharmaceuticals Presents Compelling Real-World Evidence at American Epilepsy Society Annual Meeting 2024
Exciting New Data on Behavioral Outcomes in Patients with Tuberous Sclerosis Complex Presented at AES 2024 Annual Meeting Groundbreaking research sheds light on improvements in severity of behavioral symptoms DUBLIN, Dec. 6, 2024 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced the presentation of nine company-sponsored Epidiolex® posters at the American Epilepsy Society (AES)…